Halozyme Announces argenx Received Positive Chmp Opinion for Vyvgart® (Efgartigimod Alfa) Subcutaneous Injection With Enhanze® for Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)
Halozyme宣佈argenx獲得CHMP對Vyvgart®(Efgartigimod ALFA)皮下注射與Enhanze®聯合用於慢性炎性脫髓鞘多發性神經病(CIDP)作出的積極意見。